Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer

This study has been completed.

Study NCT00017251 Information provided by National Cancer Institute (NCI)

First Received: June 6, 2001 Last Updated: April 4, 2009 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given

Publications:

Rudin CM, Kozloff M, Hoffman PC, Edelman MJ, Karnauskas R, Tomek R, Szeto L, Vokes EE. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol. 2004 Mar 15;22(6):1110-7.

Rudin C, Kosloff M, Edelman MJ, et al.: Phase I study of G3139 (oblimersen sodium), carboplatin, and etoposide in previously untreated extensive stage small cell lung cancer (SCLC). [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-2538, 631, 2003.